Dimensional Fund Advisors LP Buys 61,970 Shares of Pfizer Inc. (NYSE:PFE)

Key Points

• Dimensional Fund Advisors LP increased its stake in Pfizer Inc. by 0.2%, purchasing an additional 61,970 shares during the first quarter, now representing $743 million in value.
• Pfizer reported earnings of $0.78 per share, exceeding analysts' expectations, with quarterly revenue at $14.65 billion, reflecting a 10.3% year-over-year increase.
• The company declared a quarterly dividend of $0.43 per share, which amounts to an annualized dividend yield of 6.8%, with a payout ratio of 91.49%.

Dimensional Fund Advisors LP raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 0.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 29,326,248 shares of the biopharmaceutical company's stock after purchasing an additional 61,970 shares during the quarter. Dimensional Fund Advisors LP owned 0.52% of Pfizer worth $743,036,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Finally, Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.2%

Shares of NYSE PFE opened at $25.12 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a market cap of $142.79 billion, a PE ratio of 13.36, a P/E/G ratio of 0.90 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average of $24.56 and a two-hundred day moving average of $24.46.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 earnings per share. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PFE shares. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Redburn Atlantic reduced their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Leerink Partners reduced their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Finally, Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.